Abstract
Objective In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results.
Methods Five disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics.
Results 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location.
Conclusion ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.
Competing Interest Statement
SHP is a consultant for Zywie Bio LLC, working on a disease modifying treatment for Parkinson's disease; SCS is the Chief Scientific Officer of ADMdx, a medical diagnostics company specializing in neuroimaging of neurodegenerative disorders.
Funding Statement
This research was conducted with the support of the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario Government. Matching funds were provided by participating hospital and research institute foundations, including the Baycrest Foundation, Bruyère Research Institute, Centre for Addiction and Mental Health Foundation, London Health Sciences Foundation, McMaster University Faculty of Health Sciences, Ottawa Brain and Mind Research Institute, Queen’s University Faculty of Health Sciences, Providence Care (Kingston), St. Michael’s Hospital, Sunnybrook Health Sciences Foundation, the Thunder Bay Regional Health Sciences Centre, the University of Ottawa Faculty of Medicine, and the Windsor/Essex County ALS Association. Also, the Temerty Family Foundation provided the major infrastructure matching funds.
In addition, CF is supported by Vielight Inc, Hoffman LaRoche, Brain Canada, PCORI and the Heather and Eric Donnelly Endowment; MJ is supported by CIHR, Parkinson Society Canada, MITACS, OCE, Research Council of Norway, Abbvie, Allergan, Merz Pharma; SK is supported by Brain and Behavior Foundation, National institute on Ageing, BrightFocus Foundation, Brain Canada, Canadian Institute of Health Research, Centre for Ageing and Brain Health Innovation, Weston Brain Institute, Centre for Mental Health and Addiction Foundation and University of Toronto; DSP is supported by CIHR; ACR is supported by Canadian Institutes of Health Research Fellowship, Parkinson Society Canada, (NIH) National Institute on Deafness and Other Communication Disorders (1R21DC017255-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research ethics committees at all participating recruitment sites approved the ONDRI research protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All ONDRI data, including but not limited to data used in this article, will be available to the scientific community through the Ontario Brain Institute later this year. Please see the Ontario Brain Institute website for more information.
